FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”) is pleased to announce that a favorable Written Opinion (“WO”) has been received for Patent Cooperation Treaty (“PCT”) Patent Application No. CA2018/051387 (the “PCT Application”). The PCT Application entered national phase in the United States Patent and Trademark Office (the “USPTO”) on November 2, 2018. In the WO all 58 pending claims as filed were both novel and inventive. Based on this favorable WO, a request for accelerated examination may be filed at the USPTO. A request for accelerated examination of claims 1 to 32 was filed at the USPTO on March 6, 2019. The remaining claims 33 to 58 of the PCT Application have not yet been filed at the USPTO but may be filed in a continuation application at the USPTO.
The Company holds exclusive, irrevocable rights for application of the subject matter of the PCT Application and the US Application for use globally in the hemp and cannabis industry. In addition to the national phase entry in the United States, the PCT Application may be filed in any additional member states of the PCT, which currently includes 152 countries.
The CompleTestTM hemp and cannabis testing device applies technology to improve signal stability in the face of thermal and other fluctuations in the light source, which in turn facilitates improved sensitivity and accuracy, particularly for portable instruments. The technology applied in the CompleTestTM device is claimed in the pending PCT Application and US Application.
“The Canadian Intellectual Property Office acting as International Search Authority found no issued patents or published applications describing or making obvious the proprietary technology applied in the CompleTestTM system and claimed in the patent applications. This positive outcome at the international PCT stage, provides access to accelerated examination of all 32 claims filed in the United States. A continuation application including the other 26 claims that were found novel and inventive at the PCT stage and can also be filed in the United States, and accelerated examination will be available for those claims as well,” stated Dr. Elmar Prenner, Chief Technology Officer at FluroTech. “Additionally, the Company is developing technology for biomarking and is working with our legal counsel to draft and file patent applications protecting that technology, expanding the patent portfolio and supporting FluroTech’s commercialization of a second line of business.”
Developments on other advanced designs for future generations of the CompleTestTM system to maintain the Company’s technical lead are in progress.
“FluroTech believes it is emerging as a leader in the cannabis and hemp-house testing space with the development of badly needed technology to improve accuracy and repeatability. We believe with our data that we are meeting that need,” commented Danny Dalla-Longa, Chief Executive Officer at FluroTech. “Global regulation, rather than prohibition, of cannabis and hemp-flower products, and particularly loosening regulations around CBD products in certain countries, is encouraging FluroTech to leverage its global patent strategy. The export and import of analytical testing devices such as CompleTestTM system are not highly regulated, which increases the global testing market the Company can access. The Company is contemplating licensing opportunities in additional geographical jurisdictions and is in negotiations with international distributors to allow for quick sales expansion of the CompleTestTM system.”
About the CompleTest™ System
The CompleTest™ system is FluroTech’s flagship brand and product line. The CompleTest™ system is a portable, cost-effective, state-of-the-art hemp and cannabis testing device, able to provide fast, accurate and consistent testing results. It is designed for cultivators, processors, nurseries, researchers, other federal licensees, and even individuals with an interest in optimizing phytocannabinoid yield or consumer safety of cannabis products.
FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed in part at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ system and consumable testing kits for the CompleTest™ system.
To learn more, visit www.FluroTech.com.
Chief Executive Officer
Alistair Ross Technology Centre
Suite 111, 3553-31 Street NW
Calgary, AB T2L 2K7
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the filing of a continuation application in respect of certain of the claims, the filing of the PCT application in additional member states of the PCT, the benefits of the WO to the Company, the development of the Company’s biomarking and the intellectual property strategy in connection therewith, development for advanced designs for future generations of the Company’s technology, the Company’s position as a leader in the cannabis testing space, the U.S. and global hemp market opportunity for the CompleTestTM system, FluroTech’s ability to expand the addressable market, the ability to develop a hemp testing protocol and the timing of the protocol completion and future licensing opportunities for the Company.
The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for hemp testing protocol utilizing the CompleTestTM system in the U.S. and globally, the continuation of the trend of regulating and not prohibiting cannabis and hemp-flower products, including CBD and the success of future intellectual property filings, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industry in general, users of the Company’s CompleTestTM system and the CompleTest™ system failing to achieve the anticipated benefits of the product, changes to the anticipated regulatory regime in respect of the cannabis and hemp industry, competition from other developers of similar technology, failure to obtain patent or other intellectual property protection for the company, failure to reach commercialization of the technology and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.
The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.
Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).
Seattle Area Grocery Chain Metropolitan Market to Begin Carrying KOIOS and Fit Soda on March 22, 2021
Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.
Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.